Neisseria meningitidis colonization

Neisseria meningitidis colonization refers to the asymptomatic carriage of the bacterium in the human nasopharynx, which serves as the primary reservoir for transmission (Stephens, 1999, PubMed: 10507907). This process is a mandatory precursor to invasive meningococcal disease, such as meningitis and septicemia (CDC, 2022). Colonization is mediated by a complex array of bacterial surface structures, including Type IV pili for initial attachment and adhesins like Opa and Opc for intimate binding to host epithelial cells (Virji, 2009, PubMed: 19208853). While most colonized individuals remain asymptomatic, the bacteria can occasionally penetrate the mucosal barrier to enter the bloodstream. Therapeutic strategies targeting colonization include the use of antibiotics like rifampicin, ciprofloxacin, or ceftriaxone for chemoprophylaxis to eradicate carriage in close contacts (CDC, 2022). Additionally, meningococcal vaccines, particularly conjugate and multicomponent B vaccines, have been shown to reduce nasopharyngeal carriage, thereby contributing to herd immunity (Christensen et al., 2010, PubMed: 21124333). Preventing colonization is a critical public health objective to control the spread of meningococcal disease. Monitoring colonization rates through nasopharyngeal swabs is a key component of epidemiological surveillance.

Other names

Meningococcal carriageNasopharyngeal colonization by Neisseria meningitidisMeningococcal nasopharyngeal carriageAsymptomatic carriage of Neisseria meningitidis

Antibiotics such as rifampicin inhibit bacterial RNA polymerase, while ciprofloxacin targets DNA gyrase, leading to the eradication of the colonizing bacteria (CDC, 2022). Vaccines induce the production of bactericidal and neutralizing antibodies that prevent bacterial adhesion to the nasopharyngeal mucosa or promote complement-mediated killing of the organism (WHO, 2023).